CY1105029T1 - Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα - Google Patents

Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα

Info

Publication number
CY1105029T1
CY1105029T1 CY20061100525T CY061100525T CY1105029T1 CY 1105029 T1 CY1105029 T1 CY 1105029T1 CY 20061100525 T CY20061100525 T CY 20061100525T CY 061100525 T CY061100525 T CY 061100525T CY 1105029 T1 CY1105029 T1 CY 1105029T1
Authority
CY
Cyprus
Prior art keywords
methods
interferon
therapeutics
compositions
beta
Prior art date
Application number
CY20061100525T
Other languages
English (en)
Inventor
James G. Barsoum
Xiao-Qiang Qin
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of CY1105029T1 publication Critical patent/CY1105029T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

Παρέχονται μέθοδοι και φαρμακευτικές συνθέσεις για τροποποίηση κυττάρων ενός δέκτου θηλαστικού με DNA που κωδικοποιεί εκκρινόμενη πρωτεΐνη, όπως ανθρώπινη ιντερφερόνη, in situ. Οι μέθοδοι περιλαμβάνουν σχηματισμό συστήματος έκφρασης εκκρινόμενης πρωτεΐνης in vivo ή ex vivo και χορήγηση του συστήματος έκφρασης στο δέκτη θηλαστικό. Το σύστημα έκφρασης και οι μέθοδοι είναι χρήσιμοι για την εντοπισμένη και συστημική απελευθέρωση ιντερφερονών in situ.
CY20061100525T 1997-08-29 2006-04-17 Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα CY1105029T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (1)

Publication Number Publication Date
CY1105029T1 true CY1105029T1 (el) 2010-03-03

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100525T CY1105029T1 (el) 1997-08-29 2006-04-17 Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα

Country Status (25)

Country Link
EP (1) EP1007717B8 (el)
JP (3) JP4124565B2 (el)
KR (1) KR100699285B1 (el)
CN (1) CN100342019C (el)
AT (1) ATE316145T1 (el)
AU (1) AU740428B2 (el)
BR (1) BR9812138A (el)
CA (1) CA2300480C (el)
CY (1) CY1105029T1 (el)
CZ (2) CZ299095B6 (el)
DE (1) DE69833264T2 (el)
DK (1) DK1007717T3 (el)
EA (1) EA003256B1 (el)
EE (1) EE04873B1 (el)
ES (1) ES2257817T3 (el)
HK (1) HK1029599A1 (el)
HU (1) HU224422B1 (el)
IL (2) IL134593A0 (el)
IS (1) IS2318B (el)
NO (1) NO20000990L (el)
NZ (1) NZ503401A (el)
PT (1) PT1007717E (el)
SK (1) SK286821B6 (el)
TR (1) TR200000532T2 (el)
WO (1) WO1999010516A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1363676T3 (da) 2001-01-22 2007-07-23 Biogen Idec Inc Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
CN114630670A (zh) * 2019-06-01 2022-06-14 西韦克生物技术有限责任公司 用于将基因编辑系统递送至真核细胞的细菌平台

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
DK0707071T3 (da) * 1994-08-16 2003-11-17 Crucell Holland Bv Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
EP1007717B1 (en) 2006-01-18
KR20010023511A (ko) 2001-03-26
IL134593A (en) 2007-06-17
ES2257817T3 (es) 2006-08-01
NZ503401A (en) 2003-01-31
CZ299095B6 (cs) 2008-04-23
TR200000532T2 (tr) 2000-11-21
CA2300480A1 (en) 1999-03-04
EP1007717A2 (en) 2000-06-14
EP1007717B8 (en) 2006-05-03
IS5374A (is) 2000-02-11
KR100699285B1 (ko) 2007-03-26
IL134593A0 (en) 2001-04-30
JP3953458B2 (ja) 2007-08-08
EE200000102A (et) 2000-12-15
SK2482000A3 (en) 2000-08-14
EE04873B1 (et) 2007-08-15
CZ297314B6 (cs) 2006-11-15
DE69833264T2 (de) 2006-09-28
PT1007717E (pt) 2006-06-30
EA200000270A1 (ru) 2000-10-30
AU740428B2 (en) 2001-11-01
JP4124565B2 (ja) 2008-07-23
SK286821B6 (sk) 2009-06-05
NO20000990L (no) 2000-05-02
CN100342019C (zh) 2007-10-10
JP2004155786A (ja) 2004-06-03
HUP0002913A3 (en) 2003-08-28
EA003256B1 (ru) 2003-02-27
DE69833264D1 (de) 2006-04-06
WO1999010516A2 (en) 1999-03-04
CA2300480C (en) 2010-01-05
JP2001514010A (ja) 2001-09-11
JP4219335B2 (ja) 2009-02-04
ATE316145T1 (de) 2006-02-15
NO20000990D0 (no) 2000-02-28
IS2318B (is) 2007-11-15
DK1007717T3 (da) 2006-05-29
CZ2000733A3 (cs) 2000-06-14
HUP0002913A2 (hu) 2000-12-28
HU224422B1 (hu) 2005-08-29
WO1999010516A3 (en) 1999-05-06
CN1271391A (zh) 2000-10-25
JP2005225888A (ja) 2005-08-25
HK1029599A1 (en) 2001-04-06
BR9812138A (pt) 2000-07-18
AU9205198A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
CY1105029T1 (el) Μεθοδοι και συνθεσεις για θεραπειες καρκινου χρησιμοποιωντας γονιδια που κωδικοποιουν εκκρινομενες πρωτεϊνες οπως ιντερφερονη-βητα
DK1249490T3 (da) In vitro aktivering af cytotoksiske T-celler
DE69133228T2 (de) Dna-expressionssysteme basierend auf alphaviren
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
PA8426301A1 (es) Bikunina humana
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
GR880100198A (el) Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου.
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
ATE197719T1 (de) Verwendung von mesothelialen zellen in der gentherapie
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
ATE175237T1 (de) Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung.
FI950516A0 (fi) Interferoni-alfa/beta-sitojaproteiini, sen valmistus ja käyttö
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
AR037550A1 (es) Una composicion, un vector y un metodo utilizable en la terapia anti-tumoral, y uso de inhibidores de galectina-1(gal-1) en la preparacion de un medicamento para la terapia de celulas tumorales
AR043091A1 (es) Un conjugado que exhibe actividad de interferon beta; una secuencia de nucleotidos; un vector de expresion; una celula huesped; un metodo para reducir la inmunogenicidad y/o incrementar la vida media funcional in vivo y/o la vida media en el suero de un polipeptido interferon beta y para tratar un m